GE HealthCare Schedules July 29 Q2 Results; Launches MI-BET Theranostics Trial
GEHC•GE HealthCare will report its second-quarter 2026 financial results on July 29, 2026, before market open. GE HealthCare and Mayo Clinic launched the MI-BET theranostics study to personalize radioligand therapy for advanced prostate cancer patients.
1. Q2 2026 Earnings Release Date
GE HealthCare will report its second-quarter 2026 financial results on July 29, 2026, before market open. Investors will look for updates on revenue growth in imaging and ultrasound segments and any revisions to full-year guidance.
2. MI-BET Theranostics Research Collaboration
GE HealthCare and Mayo Clinic launched the MI-BET trial to explore molecular imaging biomarker-based end-of-therapy radioligand treatments for advanced prostate cancer. The study aims to refine patient selection and dosing to improve treatment outcomes and could expand GE HealthCare’s theranostics portfolio.
